ALK-Diagnostics in NSCLC – Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)

Journal: Pneumologie
Veröffentlichung: 01. April 2016

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Journal: Lancet Oncol.
Veröffentlichung: 06. März 2016

Clinicopathological characteristics of RET rearranged lung cancer in European patients

Journal: IASLC
Veröffentlichung: 11. Januar 2016

Developments in oncological positron emission tomography/computed tomography assessment

Journal: J Thorac Dis
Veröffentlichung: 7. Dezember 2015

Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases

Journal: Exp Mol Pathol
Veröffentlichung: 6. November 2015

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

Journal: Oncologist
Veröffentlichung: 20. Oktober 2015

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.

Journal: J Thorac Oncol.
Veröffentlichung: 10. Oktober 2015

NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Journal: Int J. Cancer
Veröffentlichung: 4. September 2015

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Journal: N Engl J Med.
Veröffentlichung: 20. August 2015

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.

Journal: AAPS J.
Veröffentlichung: 19. August 2015

Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.

Journal: Eur J Nucl Med Mol Imaging
Veröffentlichung: 18. Aug. 2015

Comprehensive genomic profiles of small cell lung cancer.

Journal: Nature
Veröffentlichung: 6. August 2015

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

Journal: J Thorac Oncol
Veröffentlichung: 10. Juli 2015

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

Journal: Cell
published 2nd of july, 2015

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

Journal: J Thorac Oncol
Veröffentlichung: 10. Jun. 2015 (Epub 10. Jun. 2015)

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Journal: Oncotarget
Veröffentlichung: 30. Apr. 2015 (Epub 30. Apr. 2015)

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.

Journal: J. Clin Oncol
Veröffentlichung: 20. März 2015 (Epub 9. Feb. 2015)

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Journal: Lancet Oncol
Veröffentlichung: 16. März 2015 (Epub 20. Feb. 2015 )

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus.

Journal: Lung Cancer
Veröffentlichung: Feb. 2015 (Epub 18. Dez. 2014 Review)

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Journal: Oncotarget. 2015 Jan 20;6(2):1315-26. Epub 2015 Feb 20.
Veröffentlichung: 20. Jan. 2015 (Epub 20. Feb. 2015)

PD-L1 expression in small cell neuroendocrine carcinomas.

Journal: Eur J Cancer
Veröffentlichung: 9. Jan. 2015

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.

Journal: Genome Biol
Veröffentlichung: 5. Jan. 2015

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung

Journal: Clin Cancer Res
Veröffentlichung: 15. Februar 2015 (Epub 9. Dezember 2014)

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy

Journal: Lancet Respir Med. 2014 Dec;2(12):966-8. doi: 10.1016/S2213-2600(14)70259-0. Epub 2014 Nov 19
Veröffentlichung: 2. Dezember 2014 (Epub 19.November 2014)

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

Journal: Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1266-7. doi: 10.1016/j.ijrobp.2014.09.038
Veröffentlicht: 1. Dezember 2014

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Journal: Oncotarget
Veröffentlichung: 26. November 2014

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Journal: Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667.Epub 2014Aug 31
Veröffentlichung: 20. September 2014 (Epub 31. August 2014)

Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib

Journal: J Thorac Oncol
Veröffentlichung: 12. September 2014 (Epub ahead of print)

CD74-NRG1 Fusions in Lung Adenocarcinoma

Journal: Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. PMID: 24469108
Veröffentlichung: 4. April 2014 (Epub 27. Januar 2014)

Ceritinib in ALK-rearranged non-small-cell lung cancer

Journal: N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107. PMID: 24670165
Veröffentlichung: 27. März 2014

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

Journal: Nat Commun. 2014 Mar 27;5:3518. doi: 10.1038/ncomms4518. PMID: 24670920
Veröffentlichung: 27. März 2014

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer

Journal: Cancer Discov. 2014 Feb;4(2):246-57. doi: 10.1158/2159-8290.CD-13-0323. PMID: 24302556
Veröffentlichung: 4. Februar 2014 (Epub 3. Dezember 2014)

A Genomics-Based Classification of Human Lung Tumors

Journal: The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM), Science Translational Medicine, October 2013. doi: 10.1126/scitranslmed.3006802
Veröffentlichung: Oktober 2013

Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small.cell lung cancer

Journal: Modern Pathology, July 2013. doi:10.1038/modpathol.2013.141
Veröffentlichung: Juli 2013

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

Journal: Lung Cancer, Vol 81, No 1, July 2013. doi:10.1016/j.lungcan.2013.02.018
Veröffentlichung: Juli 2013

Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment

Journal: Journal of Clinical Oncology, Vol 15, No 15, May 2013, doi:10.1200/jco.2012.45.9867
Veröffentlichung: Mai 2013

FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications

Journal: Translational lung cancer research, Vol 2, No 2, April 2013, doi:10.3978/j.issn.2218-6751.2013.03.03
Veröffentlichung: April 2013

Activated RET and ROS: two new driver mutations in lung adenocarcinoma

Journal: Translational lung cancer research, Vol 2, No 2, April 2013. doi: 10.3978/j.issn.2218-6751.2013.03.08
Veröffentlichung: April 2013

Tumor VEGFR:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

Journal: Journal of Clinical Investigation, Vol 123, No 4, April 2013, doi:10.1172/JCI65385
Veröffentlichung: April 2013

Molecular pathology of the lungs. New perspectives by next generation sequencing

Journal: Der Pathologe, Vol 34, No 1, February 2013. doi: 10.1007/s00292-012-1704-7
Veröffentlichung: Februar 2013

Lung Cancer: Molecular pathology and personalized therapy

Journal: Der Internist, Vol 54, No 2, February 2013. doi: 10.1007/s00108-012-3151-1
Veröffentlichung: Februar 2013

Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

Journal: PLoS One, Vol 8, No 1, January 2013. doi 10.1371/journal.pone.0053081
Veröffentlichung: Januar 2013

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models

Journal: Clinical Cancer Research, Vol 18, No 24, December 2012, doi: 10.1158/1078-0432.CCR-12-2694
Veröffentlichung: Dezember 2012

Genetic insight and therapeutic targets in squamous-cell lung cancer

Journal: Oncogene, Vol 31, No 46, November 2012, doi: 10.1038/onc.2011.640
Veröffentlichung: November 2012

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Journal: Nature Genetics,Vol 44, No 10, October 2012. doi: 10.1038/ng.2396
Veröffentlichung: Oktober 2012

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

Journal: Proc Natl Acad Sci USA, Vol 109, No 42, October 2012, doi: 10.1073/pnas.1207310109
Veröffentlichung: Oktober 2012

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET

Journal: Lung Cancer, Vol 77, No 3, September 2012, doi: 10.1016/j.lungcan.2012.05.110
Veröffentlichung: September 2012

Indications and limitations of fresh frozen sections in the pulmonary apparatus

Journal: Der Pathologe, Vol 33, No 5, September 2012, doi: 10.1007/s00292-012-1603-y
Veröffentlichung: September 2012

Comprehensive genomic characterization of squamous cell lung cancers

Journal: Nature, Vol 489, No 7417, September 2012, doi: 10.1038/nature11404
Veröffentlichung: September 2012

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Journal: Cell, Vol 150, No 6, September 2012, doi: 10.1016/j.cell.2012.08.029
Veröffentlichung: September 2012

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Journal: Clinical Cancer Research, Vol 18, No 17, September 2012, doi: 10.1158/1078-0432.CCR-11-3260
Veröffentlichung: September 2012

Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer

Journal: Journal of Clinical Oncology, Vol 30, No 27, September 2012, doi: 10.1200/JCO.2012.43.1825
Veröffentlichung: September 2012

Early palliative care for patients with metastatic cancer

Journal: Current Opinion in Oncology, Vol 24, No 4, July 2012, doi:10.1097/CCO.0b013e328352ea20
Veröffentlichung: Juli 2012

Predictive value of early and late 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

Journal: European Journal of Nuclear Medicine & Molecular Imaging, Vol 39, No 7, July 2012, doi: 10.1007/s00259-012-2118-8
Veröffentlichung: Juli 2012

Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib

Journal: Clinical Nuclear Medicine. Vol 37, No 11, doi: 10.1097/RLU.0b013e3182639747
Veröffentlichung: 2012

Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities

Journal: Clinical Cancer Research, Vol 18, No 9, May 2012 May, doi: 10.1158/1078-0432.CCR-11-2370
Veröffentlichung: Mai 2012

Recommending early integration of palliative care – does it work?

Journal: Support Care Cancer, Vol 20, No 3, March 2012, doi: 10.1007/s00520-011-1111-2
Veröffentlichung: März 2012

Personalized therapy of lung cancer

Journal: Onkologie, Vol 35, No 1, February 2012, doi: 10.1159/000334827
Veröffentlichung: Februar 2012

The association between active participation in a sports club, physical activity and social network on the development of lung cancer in smokers: a case-control study

Journal: BMC Research Notes, Vol 5, No 2, January 2012 doi: 10.1186/1756-0500-5-2
Veröffentlichung: Januar 2012

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Journal: Clinical Cancer Research. Vol 17, No 23, December 2011, doi: 10.1158/1078-0432.CCR-11-1648
Veröffentlichung: Dezember 2011

Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model

Journal: Journal of Thoracic Oncology, Vol 6, No 12, December 2011, doi: 10.1097/JTO.0b013e3182307ede
Veröffentlichung: Dezember 2011

Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET

Journal: Journal of Nuclear Medicine, Vol 52, No 12, December 2011, doi:10.2967/jnumed.111.094458
Veröffentlichung: Dezember 2011

A crucial requirement for Hedgehog signaling in small cell lung cancer

Journal: Nature Medicine, Vol 17, No 11, October 2011, doi: 10.1038/nm.2473
Veröffentlichung: Oktober 2011

Personalized therapy of lung cancer cokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

Journal: Clinical Pharmacokinetics, Vol 50, No 9, September 2011 doi: 10.2165/11593320-000000000-00000
Veröffentlichung: September 2011

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

Journal: Cancer Research, Vol 71, No 14, July 2011, doi: 10.1158/0008-5472.CAN-10-3879
Veröffentlichung: Juli 2011

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

Journal: Cancer Discovery, Vol 1, No1, June 2011, doi: 10.1158/2159-8274.CD-11-0005
Veröffentlichung: Juni 2011

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines

Journal: Clinical pharmacokinetics, Vol 50, No 6, June 2011. doi: 10.2165/11587020-000000000-00000
Veröffentlichung: Juni 2011

Blood-based gene expression signatures for early detection of lung cancer

Journal: Clinical Cancer Research, Vol 17, No 10, May 2011, doi: 10.1158/1078-0432.CCR-10-0533
Veröffentlichung: Mai 2011

Benchmarking of mutation diagnostics in clinical lung cancer specimens

Journal: PLoS One, Vol 6, No5, May 2011, doi: 10.1371/journal.pone.0019601
Veröffentlichung: Mai 2011

Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography

Journal: Journal of Clinical Oncology, Vol 29, No 13, May 2011, doi: 10.1200/JCO.2010.32.4939
Veröffentlichung: Mai 2011

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL)

Journal: Journal of Clinical Oncology, Vol 29, No 8, March 2011, doi: 10.1200/JCO.2010.29.5717
Veröffentlichung: März 2011

Molecular diagnostics of lung cancer for treatment stratification

Journal: Der Internist Vol 52, No 2, February 2012, doi: 10.1007/s00108-010-2698-y
Veröffentlichung: Februar 2011

Focal amplification of FGFR1 associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer

Journal: Science Translational Medicine, Vol 2, No 62, December 2010, doi: 10.1126/scitranslmed.3001451
Veröffentlichung: Dezember 2010

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

Journal: Nucleic Acids Research, Vol 38, No 20, November 2010, doi: 10.1093/nar/gkq579
Veröffentlichung: November 2010

Cytohesins Are Cytoplasmic ErbB Receptor Activators

Journal: Cell, Vol 143, No 2, October 2010, doi: 10.1016/j.cell.2010.09.011
Veröffentlichung: Oktober 2010

Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium

Journal: Journal of the National Cancer Institute, Vol 102, No 13, July 2010, doi: 10.1093/jnci/djq178
Veröffentlichung: Juli 2010

Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility project

Journal: Journal of palliative medicine, Vol 13, No 6, June 2010, doi: 10.1089/jpm.2009.0399
Veröffentlichung: Juni 2010

Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor

Journal: Journal of Medicinal Chemistry, Vol 53, No 7, April 2010, doi: 10.1021/jm901877j
Veröffentlichung: April 2010

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors

Journal: Journal of Thoracic Oncology, Vol 5, No 6, March 2010, doi: 10.1097/JTO.0b013e3181cf32aa
Veröffentlichung: März 2010

Identification of lung cancer with high sensitivity and specificity by blood testing

Journal: Respiratory Research, Vol 11, No 18, February 2010, doi: 10.1186/1465-9921-11-18
Veröffentlichung: Februar 2010

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

Journal: Cancer Research, Vol 70, No 3, February 2010, doi: 10.1158/0008-5472.CAN-09-3106
Veröffentlichung: Februar 2010

Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling

Journal: PLoS One, Vol 5, No 1, January 2010, doi: 0.1371/journal.pone.0008919
Veröffentlichung: Januar 2010